Exelixis (EXEL) Cash from Restructuring (2010 - 2016)
Exelixis (EXEL) posted quarterly Cash from Restructuring of $130000.0 for Q2 2016, up 143.77% year-over-year from $53328.7 in Q3 2015, and up 112.3% quarter-over-quarter from -$1.1 million in Q1 2016.
Exelixis (EXEL) Cash from Restructuring (2010 - 2016) Analysis & Trends
Exelixis' Cash from Restructuring history runs 7 years deep, the most recent figure standing at $130000.0 for Q2 2016.
- In Q2 2016, Cash from Restructuring rose 143.77% year-over-year to $130000.0; the TTM figure through Jun 2016 stood at -$4.8 million (down 82.67% YoY), while the FY2015 annual figure was -$7.2 million, down 211.9% from the prior year.
- Cash from Restructuring for Q2 2016 stood at $130000.0, up from -$1.1 million in the prior quarter.
- The five-year high for Cash from Restructuring was $8.7 million in Q4 2012, with the low at -$3.0 million in Q1 2015.
- The 5-year median for Cash from Restructuring is -$1.1 million (2014), against an average of -$606388.9.
- The sharpest annual moves came in 2014 and 2015: Cash from Restructuring jumped 193.72% in 2014, then sank 908.72% in 2015.
- Exelixis' Cash from Restructuring stood at $8.7 million in 2012, then slumped by 104.92% to -$430000.0 in 2013, then surged by 193.72% to $403000.0 in 2014, then slumped by 459.55% to -$1.4 million in 2015, then jumped by 108.97% to $130000.0 in 2016.
- Business Quant data shows EXEL's Cash from Restructuring at $130000.0 in Q2 2016, -$1.1 million in Q1 2016, and -$1.4 million in Q4 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Exelixis | 12.75 Bn | 11.91 Bn | 608.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2016 | 130,000.00 |
| Mar 31, 2016 | -1.06 Mn |
| Dec 31, 2015 | -1.45 Mn |
| Sep 30, 2015 | -2.41 Mn |
| Jun 30, 2015 | -297,000.00 |
| Mar 31, 2015 | -3.02 Mn |
| Dec 31, 2014 | 403,000.00 |
| Sep 30, 2014 | 298,000.00 |
| Jun 30, 2014 | -1.76 Mn |
| Mar 31, 2014 | -1.24 Mn |
| Dec 31, 2013 | -430,000.00 |
| Sep 30, 2013 | -1.97 Mn |
| Jun 30, 2013 | -971,000.00 |
| Mar 31, 2013 | -2.38 Mn |
| Dec 31, 2012 | 8.73 Mn |
| Sep 30, 2012 | -1.49 Mn |
| Jun 30, 2012 | -130,000.00 |
| Mar 31, 2012 | -1.87 Mn |
| Dec 31, 2011 | 3.58 Mn |
| Sep 30, 2011 | 294,000.00 |